FDA approves Tivicay for HIV infection

The FDA has on 12 August 2013 approved Tivicay (dolutegravir) from Viiv HealthCare, a new drug to treat HIV-1 infection. Tivicay is approved for use in a broad population of HIV-infected patients. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-na�ve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors. Tivicay is also approved for children ages 12 years and older weighing at least 40 kilograms (kg) who are treatment-na�ve or treatment-experienced but have not previously taken other integrase strand transfer inhibitors.